Global survey of polymyxin use: A call for international guidelines

Heiman Wertheim a,b,⁎, Kinh Van Nguyen c, Gabriel Levy Hará d, Hellen Gelband e, Ramanan Laxminarayan e,f, Johan Mouton g, Otto Cars h

a Wellcome Trust Major Overseas Program, Oxford University Clinical Research Unit, National Hospital for Tropical Diseases, Hanoi, Viet Nam
b Nuffield Department of Clinical Medicine, Centre for Tropical Diseases, Oxford, UK
c National Hospital for Tropical Diseases, Hanoi, Viet Nam
d Infectious Diseases Unit, Hospital Carlos G. Durand, Buenos Aires, Argentina
e Center for Disease Dynamics Economics and Policy, Washington, DC, USA
f Princeton University, Princeton, NJ, USA
g Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
h Action on Antibiotic Resistance (ReAct), Department of Medical Sciences, Uppsala University, Uppsala, Sweden

A R T I C L E   I N F O

Article history:
Received 23 December 2012
Revised in revised form 20 March 2013
Accepted 25 March 2013

Keywords:
Colistin
Polymyxin
Multidrug-resistant
Use
Survey
Global

A B S T R A C T

Polymyxins (polymyxin B and colistin) are older bactericidal antibiotics that are increasingly used to treat infections caused by multidrug-resistant (MDR) Gram-negative bacteria. However, dosing and clinical use of these drugs vary widely. This survey was undertaken to reveal how polymyxins are used worldwide. Data were collected through a structured online questionnaire consisting of 24 questions regarding colistin usage patterns and indications as well as colistin dosage for adult patients. The questionnaire was disseminated in 2011 to relevant experts worldwide and was completed by 284 respondents from 56 different countries. Respondents from 11/56 countries (20%) had no access to colistin; 58/284 respondents (20.4%) reported that in 2010 they experienced that colistin was not available when needed. Formulations of polymyxins used were reported as: colistimethate sodium (48.6%); colistin sulfate (14.1%); both (1.4%); polymyxin B (1.4%); and unknown. Intravenous formulations were used by 84.2%, aerosolised or nebulised colistin by 44.4% and oral colistin for selective gut decontamination by 12.7%. Common indications for intravenous colistin were ventilator-associated pneumonia, sepsis and catheter-related infections with MDR Gram-negative bacteria. Only 21.2% of respondents used a colistin-loading dose, mainly in Europe and North America. This survey reveals that the majority of respondents use colistin and a few use polymyxin B. The survey results show that colistin is commonly underdosed. Clear guidance is needed on indications, dosing and antibiotic combinations to improve clinical outcomes and delay the emergence of resistance. Colistin should be considered a last-resort drug and its use should be controlled. International guidelines are urgently needed.

© 2013 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd.

Open access under CC BY-NC-SA license.

1. Introduction

Severe multidrug-resistant (MDR) Gram-negative infections are increasing worldwide [1]. The emergence of carbapenem resistance in Gram-negative bacteria is of extreme concern as few therapeutic options remain [1]. For this reason, clinicians are increasingly using an older class of antibiotics, namely the polymyxins, most commonly colistin (polymyxin E) [2].

Colistin is a bactericidal antibiotic with a broad Gram-negative spectrum, consisting of a mixture of colistin A and colistin B, differing in their fatty acid side chain. The active compound was isolated from the bacterium Bacillus polymyxa var. colistinus in 1949 and was used in patients for the first time in 1959. Polymyxins have been used rarely since the 1970s when less toxic aminoglycosides and other antibiotics came on the market [3]. Polymyxins, developed over 50 years ago, have not been subjected to the rigorous studies to optimise dosing regimens and to demonstrate efficacy that are currently required by regulatory agencies for new drugs [3]. The appropriate dosing schedule for these drugs, how long they should be administered, and with which other antibiotics they should be used are questions remaining to be answered [2–5]. Insights into pharmacodynamic...
properties and dose–effect relationships have only recently be
tarily elucidated, but many questions still remain [6]. The lack of
documented experience with the drug and the availability of
various forms of polymyxins with different concentrations and
even units used in different dosing schemes have also led to
inappropriate use. Furthermore, access to polymyxins drugs and
other ‘forgotten antibiotics’ is limited – even in developed nations –
for economic reasons [7].

Considering that no new antibiotics covering MDR Gram-
negative bacteria can be expected to reach the market in the near
future, it is essential to use the polymyxin class of antibiotics
optimally and rationally [8,9]. Providing early adequate therapy is
critical in patients with severe infections caused by MDR bacteria
[8,9]. Underdosing runs the risk of treatment failure, poor outcome
and potentially the development and spread of polymyxin
resistance [6]. It is currently unknown which doses clinicians
use and whether they are using colistin loading doses. It is also
not known with which other drugs colistin is being combined.

To assess global polymyxin availability and parenteral use
practices, an online survey was conducted.

2. Methods

To assess global systemic polymyxin use, a 24-question survey
(see Appendix) was developed that sought information on:
characteristics of the respondents; indications for use of polymyxins;
access to polymyxins and drug type; cost of polymyxins; dosing of
polymyxins; adverse events; antibiotic combinations; and research
needs. Topical polymyxin use was not covered in this survey.

Supplementary material related to this article found, in

The questionnaire was peer-reviewed by three working groups
working on antibiotic resistance: (i) Global Antibiotic Resistance
Partnership (GARP); (ii) Action on Antibiotic Resistance (ReAct);
and (iii) the Antimicrobial Stewardship Working Group of the
International Society of Chemotherapy. The final version was
piloted and then made freely available through an online survey
website (http://www.freeonlinesurveys.com).

Professionals (e.g. infectious diseases doctors, pharmacists,
microbiologists, intensive care physicians) in relevant networks
were invited by email to complete the questionnaire. All invitees
were asked to forward the email to anyone they considered
relevant to complete the survey. The survey was open from 1 June
to 1 November 2011. Data were analysed using descriptive
statistics using SPSS v.15 (SPSS Inc., Chicago, IL).

3. Results

3.1. Respondent characteristics

The survey was completed by 284 respondents from 56 different
countries (Table 1 and Fig. 1). The majority of respondents were from
Europe, followed by the Americas, and most worked in tertiary care
teaching hospitals. Approximately one-half of the respondents
worked in hospitals with more than 500 beds. Most of the hospitals
had an intensive care unit (89.4%), department of surgery (92.6%)
and a microbiology laboratory (91.9%). All respondents had a
medical background relevant to the survey (Table 1).

3.2. Polymyxin drug access

Respondents in 11 (20%) of 56 countries reported that they had
no access to colistin at the time of the survey. Lack of access was
reported from all continents except Oceania and North America.
The countries for which no access was reported, included Bolivia,
Guatemala, Indonesia, Laos, Norway, Portugal, Russia, Uzbekistan,
Venezuela, Vietnam and Yemen (Fig. 1; data by respondent
available from the corresponding author by request). The survey
also asked about the consistency of supply of polymyxin drugs in
the respondents’ institutions. Of the 284 respondents, 58 (20.4%) reported that these drugs were unavailable for patients at least
once during the preceding year (Fig. 1).

Various forms of polymyxin drugs are available and used
worldwide. The majority of respondents used colistimethate sodium
(48.6%), followed by colistin sulfate (14.1%), both forms of colistin
(1.4%) and polymyxin B (1.4%), and the remainder did not know the
exact formulation. Eighty percent of the reported colistin sulfate use
originated from Europe and South America. No colistin sulfate was
reported from Asia. Polymyxin B was used only in South America
(Brazil and Panama) and Asia (Singapore). As Polymyxin B is rarely
used, further analysis here is limited to colistin.

The number of patients [median; interquartile range (IQR)]
treated with polymyxin drugs by region in the year 2010 was: 30
(IQR 100) in Africa; 32 (IQR 300) in Asia; 5 (IQR 24) in Europe; 2
(IQR 20) in North America; 2 (IQR 4) in Oceania; and 15 (IQR 30) in
South America.

3.3. Indications for colistin

Colistin is administered via different routes, depending on the
indication. Of the 284 respondents, 84.2% used colistin intrave-
nously, 44.4% used aerosolised or nebulised colistin and 12.7% used
oral colistin for selective gut decontamination. Common indica-
tions for intravenous colistin use were ventilator-associated
pneumonia, sepsis and catheter-related infections with MDR
Gram-negative bacteria. Nebulised colistin was often used in cystic
fibrosis patients. Colistin was used most commonly against
Acinetobacter baumannii and Pseudomonas aeruginosa. Oral colistin
for selective gut decontamination was most frequently reported
from Europe, followed by North America. No African respondents
reported oral colistin use.

3.4. Dosing of colistin

The dosing schedule for an adult patient with a weight of 70 kg
and normal renal function (the standard case posed in the
questionnaire) varied considerably, partly reflecting the different
kinds of formulations. Dosing data were reported in million
international units (MIU) (37.3%), mg/kg/day (21.5%) and mg (8.8%) (see Table 2 for dosing conversion). For those reporting in MIU, the median total daily dose was 6.0 MIU (range 1.5–9.0 MIU) administered three times per day (range 1–4 times per day). For those reporting in mg/kg/day, the median colistin dose was 5 mg/kg/day (range 1.5–6.0 mg/kg/day). Those who also administered a loading dose (see below) reported a higher maintenance dose compared with those who did not use a loading dose: median of 9 MIU versus 6 MIU. Approximately one-quarter (26.4%) of the respondents were dosing their patients in the lower range (≤2.5 mg/kg/day or ≤6 MIU). The median duration of colistin treatment was 14 days. Less than one-third (29%) reported adjusting the dose in obese patients. Dosing strategies for patients on haemodialysis varied, most indicating that they halved the dose.

Evidence from pharmacokinetic/pharmacodynamic (PK/PD) studies indicates that a colistin loading dose may be beneficial for patients with severe MDR Gram-negative infections. Of the respondents, only 21.2% reported a loading dose and most of these were in Europe and North America. No Asian respondent reported that they used a loading dose. In Europe, the most common loading dose was 9 MIU and in South America it was 4.5 MIU (the loading dosage was provided via a separate email request to those using a loading use).

3.5. Drug combinations

Table 3 lists the antibiotics used with colistin, according to the relative frequency. The most common antibiotic combination was with a carbapenem. Other relatively common combinations were aminoglycosides, tigecycline, rifampicin and piperacillin/tazobactam. According to respondents, the choice of a second antibiotic depends on the type of infection being treated and the susceptibility profile of the cultured bacteria, if available. The most important drugs to combine with polymyxins to study in a clinical trial are considered to be tigecycline and piperacillin/tazobactam, according to a majority of survey respondents.

4. Discussion

To our knowledge, this is the first global survey on polymyxin use. Respondents were a self-selected group and we do not portray the results as an unbiased sample. Despite this, the study provides important insights into the current global pattern of access to and use of these drugs. As only a few respondents reported polymyxin B use, the discussion focuses on colistin.

In general, the indications for use of systemic colistin are similar across the regions: severe infections caused by MDR Gram-negative...
bacteria, such as A. baumannii and P. aeruginosa. However, there are major variations in the dosing regimens, with several sites using relatively low doses, and a loading dose of colistin was not reported by most respondents. PK/PD studies found that it takes several days to develop adequate concentrations of colistin in human plasma [5,10]. These studies suggest that loading doses are required to achieve adequate levels of colistin as early as possible [5,10]. Providing early adequate therapy is critical in patients with severe infections due to MDR bacteria [10].

In a recent discussion on dosing of colistin, and taking into account the PK/PD properties of colistin, a 9 MIU loading dose and 4.5 MIU every 12 h was suggested to be one of the optimum dosing alternatives (colistin fact sheet available at http://aida-project.eu). In particular, the loading dose was regarded to be essential, since the simulations strongly indicate that it takes up to several days before steady state is reached [10]. However, even then concentrations required for optimal efficacy may not be reached. In addition, PK profiles vary widely between patients, suggesting that therapeutic drug monitoring could be beneficial.

Clinicians reported reluctance to use higher doses because of concerns about toxicity [3]. However, based on various studies, these concerns may be misplaced and respondents that use a loading dose confirm little toxicity issues of this strategy. Colistin has been shown to have a better safety profile than thought previously, perhaps even better than the safety profile of aminoglycosides [3,11,12]. The risk of toxicity may be favoured above inadequate treatment of a severe infection due to MDR bacteria. Clearly, more should be known about these drugs, but we are concerned that underdosing may be a serious issue as this is related to the emergence of resistant bacteria [13].

However, excessive use of colistin needs to be addressed. More than 10% of the respondents mentioned that they also used polymyxins as part of a selective gut decontamination regimen. The use of polymyxins for this purpose needs to be weighted by the risk of resistance development in a world where carbapenem resistance is emerging and spreading [1]. Furthermore, colistin is used in large amounts in agriculture, particularly in Asia (Do Thuy Nga, GARP co-ordinator Vietnam, personal communication). The reasons for use in agriculture require further investigation and a case made for banning polymyxins for agricultural use.

This survey revealed important variations in the use of polymyxins across the world, supporting the need for the development of clear guidelines covering the indication, dosage and duration of polymyxins. Many questions regarding dosing and combinations with other antibiotics remain, and studies are under way to answer at least some of these. However, guidelines can and should be developed based on current evidence and revised as new information becomes available. The European Union-funded AIDA project tries to address these issues and has made colistin fact sheets and dosing conversion tables available (http://aida-project.eu/back-ground-information/fact-sheets/91-fact-sheets-public/84-colistin-fact-sheet-public). As new classes of antibiotics for MDR Gram-negative bacteria are not within sight, we need to preserve these last-resort antibiotics.

### Funding

This work was funded by the Global Antibiotic Resistance Partnership (GARP, USA) and the Wellcome Trust (UK). The Wellcome Trust had no role in the design, data collection, analysis, interpretation, drafting of the paper or the decision to submit for publication. GARP staff were part of the study team and therefore had a role in all aspects of this project.

### Competing interests

None declared.

### Ethical approval

Not required.

### Acknowledgments

The authors would like to thank the following organisations and individuals for helping to disseminate the survey: Global Antibiotic Resistance Partnership (GARP, USA); Working Group on Antimicrobial Stewardship of the International Society of Chemotherapy (ISC, UK); Action on Antibiotic Resistance (ReAct, Sweden); Dr Dennis Dixon (National Institute of Health, USA); European Society for Clinical Microbiology and Infectious Diseases (ESCMID); Dr Gail Thomson (Health Protection Agency, UK); Dr Jeremy Farrar (Oxford University Clinical Research Unit, Vietnam); AIDA project; and the Pan-American Infectious Diseases Association.

### References


